Boston Childrens Hospital

1. Novartis Pharmaceuticals Corporation $17,761,349 31 payments
2. E.R. Squibb & Sons, L.L.C. $2,153,472 17 payments
3. Retrophin, Inc. $387,434 4 payments
4. Janssen Research & Development, LLC $228,829 13 payments
5. Sobi, Inc $208,219 15 payments
6. Eisai Inc. $192,780 17 payments
7. Acacia Pharma Inc $169,851 8 payments
8. Genentech, Inc. $158,953 3 payments
9. Organon LLC $146,975 3 payments
10. Roche Diagnostics Corporation $120,380 7 payments

1. A Phase 3 Study of Eltrombopag VS Standard First Line Management for Newly Diagnosed Immune Thrombocytopenia Itp in Children $8,499,998 5 payments
2. Evaluating the Safety and Efficacy of Everolimus in the Treatment of Neurocognitive and Social Deficits in Patients With Pten Mutation $7,812,631 3 payments
3. A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-Term Dosing for Graft Versus Host Disease Prophylaxis: Aba3 $1,116,674 2 payments
4. A Phase II Study to Evaluate the Long-Term Safety and Efficacy of Alpelisib in Patients With Pik3ca-Related Overgrowth Spectrum (Pros) Who Previously Participated in Study Cbyl719f12002 (Epik-P1) $685,317 4 payments
5. Advancing Transplantation Outcomes in Children $418,988 3 payments
6. A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-Term Dosing for Graft Versus Host Disease Prophylaxis Aba3 $368,541 1 payment
7. Ot-58 As An Enzyme Therapy for Patients With Homocystinuria Caused By Cystathionine Beta-Synthase Deficiency $354,723 2 payments
8. Multicenter Open Label Study to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics Oflcz696 Followed By A 52 Week Randomized Double Blind Parallel Group Active Controlled Study to Evaluate the Efficacy and Safety of Lcz696 Compared With En $194,808 2 payments
9. A Phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab With Or Without Hydroxyurea Hydroxycarbamide in Sequential Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso Occlusive Cris $186,247 2 payments
10. Ava-Ped-301 $182,189 14 payments

1. Other $557,285 12 payments
2. Patient care $151,664 4 payments
3. Overhead $42,120 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.